Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Progress in MPNs

Mary Frances McMullin • 29 Mar 2017
BSH 2017
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib
MAJIC

Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses trials and progress in myeloproliferative neoplasms (MPNs) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin discusses the role of ruxolitinib in myelofibrosis, the failure many second-line agents and the importance of having another agent. She also mentions how her group has reported on the polycythaemia vera (PV) and essential thrombocythaemia (ET) MAJIC trial (ISRCTN61925716).

More from Mary Frances McMullin

1:32
Hereditary erythrocytosis
Mary Frances McMullin • 25 Oct 2021
1:27
Driver mutations in MPNs
Mary Frances McMullin • 25 Oct 2021
1:00
What to look out for at ASH 2019: MPNs
Mary Frances McMullin • 15 Nov 2019
3:02
Updated BSH guidelines for non-clonal polycythemia
Mary Frances McMullin • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals